Sophie Vadeboncoeur1, Benoît Côté2. 1. Division of Dermatology, Université de Montréal, Montreal, QC, Canada sophie.vadeboncoeur@umontreal.ca. 2. Division of Dermatology, Université de Montréal, Montreal, QC, Canada.
Abstract
BACKGROUND: Doxorubicin is an antineoplastic agent frequently used in diverse cancer regimens. Cutaneous adverse effects have frequently been reported with its use. However, a flagellate-like dermatitis is not mentioned in the literature. OBJECTIVE: The investigators report a case of toxic erythema of chemotherapy with a flagellate pattern induced by doxorubicin. METHODS AND RESULTS: A 75-year-old woman with endometrial cancer received doxorubicin as part of her treatment. After her third cycle, she presented a pruritic vesiculobullous eruption, with linear elements that left hyperpigmented streaks on follow-up. A biopsy was compatible with a drug eruption. CONCLUSION: Doxorubicin is a well-known cause of toxic erythema of chemotherapy. As seen in this patient, the investigators suggest that it also be added to the list of causes of flagellate dermatosis.
BACKGROUND:Doxorubicin is an antineoplastic agent frequently used in diverse cancer regimens. Cutaneous adverse effects have frequently been reported with its use. However, a flagellate-like dermatitis is not mentioned in the literature. OBJECTIVE: The investigators report a case of toxic erythema of chemotherapy with a flagellate pattern induced by doxorubicin. METHODS AND RESULTS: A 75-year-old woman with endometrial cancer received doxorubicin as part of her treatment. After her third cycle, she presented a pruritic vesiculobullous eruption, with linear elements that left hyperpigmented streaks on follow-up. A biopsy was compatible with a drug eruption. CONCLUSION:Doxorubicin is a well-known cause of toxic erythema of chemotherapy. As seen in this patient, the investigators suggest that it also be added to the list of causes of flagellate dermatosis.